לוסרדקס 50 ישראל - עברית - Ministry of Health

לוסרדקס 50

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

לוסרדקס 50 ישראל - עברית - Ministry of Health

לוסרדקס 50

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

לוסרדקס 100 ישראל - עברית - Ministry of Health

לוסרדקס 100

dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoi

לוסרדקס 100 ישראל - עברית - Ministry of Health

לוסרדקס 100

dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended.renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoin

בוסנטן טבע  125 מג ישראל - עברית - Ministry of Health

בוסנטן טבע 125 מג

abic marketing ltd, israel - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 125 mg - bosentan

בוסנטן טבע  62.5 מג ישראל - עברית - Ministry of Health

בוסנטן טבע 62.5 מג

abic marketing ltd, israel - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 62.5 mg - bosentan

אוקסאאר פלוס ישראל - עברית - Ministry of Health

אוקסאאר פלוס

organon pharma israel ltd., israel - hydrochlorothiazide; losartan potassium - טבליה - losartan potassium 50 mg; hydrochlorothiazide 12.50 mg - losartan and diuretics - losartan and diuretics - ocsaar plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hyperfension adn left ventricular hypertrophy.

לוסרטאן פלוס טבע ישראל - עברית - Ministry of Health

לוסרטאן פלוס טבע

teva pharmaceutical industries ltd, israel - hydrochlorothiazide; losartan potassium - טבליה - hydrochlorothiazide 12.5 mg; losartan potassium 50 mg - losartan and diuretics - losartan and diuretics - losartan plus teva is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.

בוסנטן תרו 125 מג ישראל - עברית - Ministry of Health

בוסנטן תרו 125 מג

taro international ltd, israel - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 125 mg - bosentan

בוסנטן תרו 62.5 מג ישראל - עברית - Ministry of Health

בוסנטן תרו 62.5 מג

taro international ltd, israel - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 62.5 mg - bosentan